Abstract
574 Background: The NCCN recommends serial bone mineral density (BMD) measurement with dual energy x-ray absorptiometry (DXA) to diagnose and treat AI-associated osteoporosis. The FRAX algorithm identifies additional patients with ORFR who may benefit from anti-resorptive therapy (ART). The TBS, which measures bone microstructure by DXA, is an independent indicator of ORFR. Here, we retrospectively evaluate the utility of a combined screening approach (BMD+FRAX+TBS) in identifying ORFR at baseline and following AI. Methods: Breast cancer patients > 60 years, treated with AI and no ART between 2006-12, who had serial DXA at Memorial Sloan Kettering Cancer Center were identified (n= 74). BMD, FRAX, and TBS were evaluated at baseline (< 3 months from AI initiation) and at 12-24 months, and various screening strategies for identifying ORFR were assessed. Based on National Osteoporosis Foundation criteria and Manitoba TBS study fracture rates, ORFR was defined as: BMD T-score≤-2.5; ≥3% hip or ≥20% osteoporosis...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call